IL152688A0 - Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system - Google Patents

Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system

Info

Publication number
IL152688A0
IL152688A0 IL15268801A IL15268801A IL152688A0 IL 152688 A0 IL152688 A0 IL 152688A0 IL 15268801 A IL15268801 A IL 15268801A IL 15268801 A IL15268801 A IL 15268801A IL 152688 A0 IL152688 A0 IL 152688A0
Authority
IL
Israel
Prior art keywords
donors
disorders
treatment
combination
nervous system
Prior art date
Application number
IL15268801A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL152688A0 publication Critical patent/IL152688A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Saccharide Compounds (AREA)
IL15268801A 2000-05-10 2001-05-10 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system IL152688A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10022856A DE10022856A1 (de) 2000-05-10 2000-05-10 Therapeutische Kombination von Liponsäure und C1-Donoren zur Behandlung von Störungen des Zentralen Nervensystems
PCT/EP2001/005359 WO2001085165A2 (de) 2000-05-10 2001-05-10 Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems

Publications (1)

Publication Number Publication Date
IL152688A0 true IL152688A0 (en) 2003-06-24

Family

ID=7641502

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15268801A IL152688A0 (en) 2000-05-10 2001-05-10 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system

Country Status (9)

Country Link
US (1) US20030148991A1 (de)
EP (1) EP1289521A2 (de)
JP (1) JP2003532674A (de)
AU (1) AU6742401A (de)
CA (1) CA2408666A1 (de)
DE (1) DE10022856A1 (de)
IL (1) IL152688A0 (de)
WO (1) WO2001085165A2 (de)
ZA (1) ZA200209940B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317920B1 (it) * 2000-10-20 2003-07-15 Univ Roma S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer.
DE10255242A1 (de) 2002-11-26 2004-06-03 Basf Ag Verfahren zur Reinigung von Liponsäure
ITMI20030831A1 (it) * 2003-04-22 2004-10-23 Laboratorio Chimico Int Spa Sale basico dell'acido tiottico con la l-carnitina.
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
JPWO2005046668A1 (ja) * 2003-11-14 2007-05-24 持田製薬株式会社 言語障害予防・治療剤
EP1645276A1 (de) * 2004-10-08 2006-04-12 Wageningen Centre for Food Sciences Behandlung von neurodegenerativen Erkrankungen
FR2884421B1 (fr) * 2005-04-15 2007-08-10 Virbac Sa Nouveaux moyens de regulation des troubles du comportement chez les animaux de compagnie
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
AU2011215669B2 (en) * 2010-02-12 2015-06-04 HedoniaUSA, Inc. Compositions and methods for treating depression
EP2882304A1 (de) * 2012-08-07 2015-06-17 Buck Institute For Research On Aging Mehrkomponentige formulierung zur verbesserung der neurologischen funktion
CA3042699A1 (en) * 2016-11-03 2018-08-09 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4630M (de) * 1965-06-09 1966-11-28
AR221676A1 (es) * 1974-07-12 1981-03-13 Bioresearch Sas Procedimiento para la preparacion de sales estables sulfonicas y/o sulfuricas de la s-adenosil-l-metionina,particularmente utiles como donadores especificos de metilo para las reacciones bioquimicas de transferencia del grupo ch3;asi como tambien las reacciones fundamentales en el metabolismo lipilico,protilico y glucidico
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
DE4343592C2 (de) * 1993-12-21 1998-04-16 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure und dessen Metaboliten in Form der freien Säure oder als Salze oder Ester oder Amide zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystems

Also Published As

Publication number Publication date
WO2001085165A2 (de) 2001-11-15
ZA200209940B (en) 2003-12-09
JP2003532674A (ja) 2003-11-05
WO2001085165A3 (de) 2002-05-02
AU6742401A (en) 2001-11-20
EP1289521A2 (de) 2003-03-12
CA2408666A1 (en) 2002-11-08
DE10022856A1 (de) 2001-11-15
US20030148991A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
EP1471909A4 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von erkrankungen des zentralen nervensystems
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
AU9287401A (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
HU0003863D0 (en) Alpha-sulfonylamino hidroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
EP1434801A4 (de) Behandlung von störungen des zentralen nervensystems
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
AU2002211612A1 (en) Methods for the treatment of a traumatic central nervous system injury
HUP0501017A2 (en) Methods and compositions for treatment of central nervous system disorders
AU6910600A (en) Methods for the treatment of mental disorders
EP1356278A4 (de) Verfahren und zusammensetzungen zur identifikation und behandlung von neurodegenerativen erkrankungen
AU4541101A (en) Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
IL152688A0 (en) Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
AU9527001A (en) Treatment of T cell disorders
EP1187604A4 (de) Verbindungen und methoden zur behandlung von störungen duch post-traumatischen stress
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
EP1331010A4 (de) Mittel zur prävention und behandlung von erkrankungen des zentralen nervensystems
IL140540A0 (en) Treatment of anxiety disorders
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
AU4687501A (en) Medicine for treating traumatic brain injury and other neuronal disorders
GB0010496D0 (en) Treatment of conditions of the central nervous system